Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We present results on the growth of damage in 29 fatigue tests of human femoral cortical bone from four individuals, aged 53-79. In these tests we examine the interdependency of stress, cycles to failure, rate of creep strain, and rate of modulus loss. The behavior of creep rates has been reported recently for the same donors as an effect of stress and cycles. In the present paper we first examine how the evolution of damage (drop in modulus per cycle) is associated with the stress level or the "normalized stress" level (stress divided by specimen modulus), and results show the rate of modulus loss fits better as a function of normalized stress. However, we find here that even better correlations can be established between either the cycles to failure or creep rates versus rates of damage than any of these three measures versus normalized stress. The data indicate that damage rates can be excellent predictors of fatigue life and creep strain rates in tensile fatigue of human cortical bone for use in practical problems and computer simulations.
 ...
PMID:Damage rate is a predictor of fatigue life and creep strain rate in tensile fatigue of human cortical bone samples. 1597 98

The first pyrethroid pesticide, allethrin, was identified in 1949. Allethrin and other pyrethroids with a basic cyclopropane carboxylic ester structure are type I pyrethroids. The insecticidal activity of these synthetic pyrethroids was enhanced further by the addition of a cyano group to give alpha-cyano (type II) pyrethroids, such as cypermethrin. The finding of insecticidal activity in a group of phenylacetic 3-phenoxybenzyl esters, which lacked the cyclopropane ring but contained the alpha-cyano group (and hence were type II pyrethroids) led to the development of fenvalerate and related compounds. All pyrethroids can exist as at least four stereoisomers, each with different biological activities. They are marketed as racemic mixtures or as single isomers. In commercial formulations, the activity of pyrethroids is usually enhanced by the addition of a synergist such as piperonyl butoxide, which inhibits metabolic degradation of the active ingredient. Pyrethroids are used widely as insecticides both in the home and commercially, and in medicine for the topical treatment of scabies and headlice. In tropical countries mosquito nets are commonly soaked in solutions of deltamethrin as part of antimalarial strategies. Pyrethroids are some 2250 times more toxic to insects than mammals because insects have increased sodium channel sensitivity, smaller body size and lower body temperature. In addition, mammals are protected by poor dermal absorption and rapid metabolism to non-toxic metabolites. The mechanisms by which pyrethroids alone are toxic are complex and become more complicated when they are co-formulated with either piperonyl butoxide or an organophosphorus insecticide, or both, as these compounds inhibit pyrethroid metabolism. The main effects of pyrethroids are on sodium and chloride channels. Pyrethroids modify the gating characteristics of voltage-sensitive sodium channels to delay their closure. A protracted sodium influx (referred to as a sodium 'tail current') ensues which, if it is sufficiently large and/or long, lowers the action potential threshold and causes repetitive firing; this may be the mechanism causing paraesthesiae. At high pyrethroid concentrations, the sodium tail current may be sufficiently great to prevent further action potential generation and 'conduction block' ensues. Only low pyrethroid concentrations are necessary to modify sensory neurone function. Type II pyrethroids also decrease chloride currents through voltage-dependent chloride channels and this action probably contributes the most to the features of poisoning with type II pyrethroids. At relatively high concentrations, pyrethroids can also act on GABA-gated chloride channels, which may be responsible for the seizures seen with severe type II poisoning. Despite their extensive world-wide use, there are relatively few reports of human pyrethroid poisoning. Less than ten deaths have been reported from ingestion or following occupational exposure. Occupationally, the main route of pyrethroid absorption is through the skin. Inhalation is much less important but increases when pyrethroids are used in confined spaces. The main adverse effect of dermal exposure is paraesthesiae, presumably due to hyperactivity of cutaneous sensory nerve fibres. The face is affected most commonly and the paraesthesiae are exacerbated by sensory stimulation such as heat, sunlight, scratching, sweating or the application of water. Pyrethroid ingestion gives rise within minutes to a sore throat, nausea, vomiting and abdominal pain. There may be mouth ulceration, increased secretions and/or dysphagia. Systemic effects occur 4-48 hours after exposure. Dizziness, headache and fatigue are common, and palpitations, chest tightness and blurred vision less frequent. Coma and convulsions are the principal life-threatening features. Most patients recover within 6 days, although there were seven fatalities among 573 cases in one series and one among 48 cases in another. Management is supportive. As paraesthesiae usually resolve in 12-24 hours, specific treatment is not generally required, although topical application of dl-alpha tocopherol acetate (vitamin E) may reduce their severity.
 ...
PMID:Poisoning due to pyrethroids. 1618 Sep 29

On March 15, 2005, the U.S. Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Five hundred seventy-three glioblastoma multiforme patients were randomized to receive either temozolomide + radiotherapy (n = 287) or radiotherapy alone (n = 286). Patients in the temozolomide + radiotherapy arm received concomitant temozolomide (75 mg/m2) once daily for the duration of radiation therapy (42-49 days). This was followed, 4 weeks later, by six cycles of temozolomide, 150 or 200 mg/m2 daily for 5 days, every 4 weeks. Patients in the control arm received radiotherapy only. In both arms, radiotherapy was delivered as 60 Gy/30 fractions to the tumor site with a 2 to 3 cm margin. Pneumocystis carinii pneumonia prophylaxis was required during temozolomide + radiotherapy treatment and was continued until recovery of lymphocytopenia (Common Toxicity Criteria grade <1). At disease progression, temozolomide salvage treatment was given to 161 of 282 patients (57%) in the radiotherapy alone arm, and to 62 of 277 patients (22%) in the temozolomide + radiotherapy arm. Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival. The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001). Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone). Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.
 ...
PMID:Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. 1620 62

A case of acute intoxication involving lidocaine and chlorpheniramine (an antihistamine) in a 13-month-old child after ingestion of a commercial topical agent is presented. The major toxic reaction consisted of convulsion, coma, tachycardia, fever, and fatigue. This report shows that parents and physicians should be made aware of the hazards of lidocaine and overdose of other topical agents in infants and children.
 ...
PMID:Acute intoxication of lidocaine and chlorpheniramine: report of one case. 1664 43

The long-range reversible deformation of vertebrate arteries is primarily mediated by elastin networks that endure several million deformation cycles without appreciable fatigue. To determine how elastin contributes to the composite arterial properties, we studied the three-dimensional microstructure and biomechanics of isolated elastin. We initially estimated the sensitivity of these studies by comparing two elastin isolation protocols, autoclaving and alkali-extraction, and measured their effect on isolated elastin using uniaxial tests and histology. These studies show that autoclaved tissues have a trend for higher modulus (900.79+/-678.02 kPa) than alkali-extracted samples (417.74+/-162.23 kPa)albeit with higher collagen-proteoglycan impurities, and (2) greater optical density (78.6+/-9.1%) than alkali-extracted groups (46.2+/-5.9%), suggesting that autoclaving is superior to alkali-extraction for biomechanical tests on elastin. Using these data we show that an isotopic Mooney-Rivlin model cannot adequately represent arterial elastin. The neo-Hookean model, with coefficient 162.57 (+/-115.44) kPa for autoclaved and 76.94 (+/-27.76) kPa for alkali-extracted samples, fits the uniaxial data better. Autoclaved elastins also show linear stress-strain response and equal stiffness in circumferential and axial directions suggesting equal number of layers in these directions and that elastin may help distribute tensile stresses during vessel inflation. Histology of autoclaved and control porcine arteries reveals axial elastin fibers in intimal and adventitial layers but circumferential medial fibers. We propose an orthotropic material symmetry for arterial elastin with two orthogonally oriented and symmetrically placed mechanically equivalent fibers. An exact form of the constitutive equation will be obtained in a future study.
 ...
PMID:Determination of strain energy function for arterial elastin: Experiments using histology and mechanical tests. 1664 25

Some penaeids are active swimmers, undertaking migrations of hundreds of nautical miles. At present, however, very little is known of swimming ability in penaeid shrimps. The aim of the present study is to investigate swimming endurance of whiteleg shrimp, Litopenaeus vannamei, against one of five flow velocities (5.41, 6.78, 8.21, 10.11, and 11.47 cm s(-1)) for up to 9000 s at 20 degrees C in a swimming channel. Body mass, hemolymph total protein concentration, and hemolymph glucose level were measured before swimming and immediately following swimming to evaluate physiological effect of swimming in L. vannamei. No shrimp swam the full 9000 s at any of the velocities tested. The swimming endurance decreased as swimming speed was increased. The relationship between swimming endurance (t, in s) and swimming speed (v, in cm s(-1)) can be described by the Curve Estimation: v.t0.38 = 159.64 (R2 = 0.94). The swimming ability index (SAI), defined as SAI = integral 0-9000 vdt x 10(-4) (cm) was found to be 7.28 cm for the shrimp tested. Swimming to fatigue leads to severe loss of body mass, hemolymph total protein concentration, and hemolymph glucose level in L. vannamei (P < 0.05). Furthermore, these decreases and swimming speed showed significantly polynomial relationships (P < 0.05). The results suggest that the power model fits well to the observed endurance estimates and the SAI is a good index to quantitatively describe the overall swimming ability of L. vannamei. Furthermore, hemolymph total protein concentration may be used as a rapid and reliable indicator to assess the penaeid shrimps' swimming speed and hence swimming ability.
 ...
PMID:Swimming ability and physiological response to swimming fatigue in whiteleg shrimp, Litopenaeus vannamei. 1684 24

We described a case of thrombotic thrombocytopenic purpura (TTP) with systemic lupus erythematosus (SLE). A-60-year old woman was admitted to our hospital because of fever, disconsciousness, and general fatigue. 32 years ago, she was diagnosed as SLE with Raynaud's phenomenon, rash, photosensitivity, arthritis, lymphocytopenia, and ANA. Her SLE was well controlled with 10 mg predonisolone as a maintance dose until several weeks ago. On admission, severe thrombocytopenia (0.7x10(4)/microl) and other laboratory data revealed microangiopathic hemolytic anemia and renal dysfunction, Immediately after diagnosed as TTP, plasma exchange and corticosteroid therapy started. In spite of the treatment, disconsciousness progressed and systemic convulsion occurred and died 4 days after admission. Autopsied examination revealed diffuse microvascular hyalinized thrombi in heart, kidney, liver, spleen, and pancreas. Some microvascular thrombi were detected in lymph nodes, bone marrow, intestine. Pathological diagnosis of TTP was made on microvascular hyalinized platelet thrombi in organs. Von Willebrand factor-cleaving protease (VWF-CP) activity in plasma on set is less than 0.5 percent of normal and inhibitor for VWF-CP was detected. We here report a valuable case for analysis of pathogenesis in SLE-TTP.
 ...
PMID:[A case of thrombotic thrombocytopenic purpura with systemic lupus erythematosus]. 1707 94

The patient was a 33 year female. In 2001, she was diagnosed with systemic lupus erythematosus (SLE) and treated with prednisolone and ciclosporin. In May 2006, she noticed slight muscle weakness in the bilateral lower limbs. In July of the same year, she experienced gait difficulty and was admitted to our hospital because of fatigue, appetite loss, fever and disorientation. Soon afterwards, she had a fit of general convulsion and suffered from urinary retention and fecal incontinence. A brain magnetic resonance image revealed atrophy of the thoracic cord in T2 weighted images, and cerebrospinal fluid examination showed high total protein and interleukin-6 concentration, indicating complication of lupus myelitis as well as cerebral involvement. Steroid pulse and oral prednisolone treatment resulted in ameriolation of cerebral complications such as disorientation and convulsion, but muscle weakness and paresthesia in the lower limbs and urinary retention persisted. Cyclophosphamide pulse therapy was started and resulted in a marked recovery from muscle weakness, paresthesia and urinary retention, and she could discharge. We conclude that steroid and cyclophosphamide pulse therapy for a SLE patient with CNS lupus and lupus myelitisis is effective for ameriolation of symptoms such as disorientation, convulsion, urinary retension, fecal incontinence, muscle weakness and paresthesia in the lower limbs as well as elevated level of serum anti-ribosomal P antibody.
 ...
PMID:[Successful therapy with steroid and cyclophosphamide pulse for CNS lupus and lupus myelitis]. 1798 83

Cement mantles around metallic implants have pre-existing flaws (shrinkage induced cracks, laminations, and endosteal surface features) and their fatigue failure is related to the fatigue crack propagation (FCP) rate of bone cement. We estimated the relevant in vivo range of cyclic stress intensity factor (DeltaK) around a generic femoral stem (0-1 MPa square root(m)) and determined that previous FCP data did not adequately cover this range of DeltaK. Vacuum-mixed standard bone cement was machined into ASTM E647 standard compact notched tension specimens. These were subject to sinusoidal loading (R = 0.1) at 5 Hz in 37 degrees C DI water, covering a DeltaK range of 0.25-1.5 MPa square root(m) (including a decreasing DeltaK protocol). FCP-rate data is normally reduced to a power-law fit relating crack growth rate (da/dn) to DeltaK. However, a substantial discontinuity was observed in our data at around DeltaK = 1, so two power-law fits were used. Over the physiologically plausible range of DeltaK, cracks grew at a rate of 2.9 E -8 x DeltaK(2.6) m/cycle. Our data indicated that FCP-rates for 0.5 > DeltaK > 0.3 MPa square root(m) are between 10 E -8 and 10 E -8 m/cycle, 1 or 2 orders of magnitude greater than predicted by extrapolating from previous models based on higher DeltaK data.
 ...
PMID:Fatigue crack propagation rates in PMMA bone cement cannot be reduced to a single power law. 1816 13

We present a curve-fitting approach that permits quantitative comparisons of fatigue profiles obtained with different stimulation protocols in isolated slow-twitch soleus and fast-twitch extensor digitorum longus (EDL) muscles of mice. Profiles from our usual stimulation protocol (125 Hz for 500 ms, evoked once every second for 100-300 s) could be fitted by single-term functions (sigmoids or exponentials) but not by a double exponential. A clearly superior fit, as confirmed by the Akaiki Information Criterion, was achieved using a double-sigmoid function. Fitting accuracy was exceptional; mean square errors were typically <1% and r(2) > 0.9995. The first sigmoid (early fatigue) involved approximately 10% decline of isometric force to an intermediate plateau in both muscle types; the second sigmoid (late fatigue) involved a reduction of force to a final plateau, the decline being 83% of initial force in EDL and 63% of initial force in soleus. The maximal slope of each sigmoid was seven- to eightfold greater in EDL than in soleus. The general applicability of the model was tested by fitting profiles with a severe force loss arising from repeated tetanic stimulation evoked at different frequencies or rest periods, or with excitation via nerve terminals in soleus. Late fatigue, which was absent at 30 Hz, occurred earlier and to a greater extent at 125 than 50 Hz. The model captured small changes in rate of late fatigue for nerve terminal versus sarcolemmal stimulation. We conclude that a double-sigmoid expression is a useful and accurate model to characterize fatigue in isolated muscle preparations.
 ...
PMID:Double-sigmoid model for fitting fatigue profiles in mouse fast- and slow-twitch muscle. 1834 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>